FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549	
vvasilington,	D.O. 20070	

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

Estimated average burden hours per response: Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-

1(c). Se	ee Instruction	on 10.															
Name and Address of Reporting Person* Nuss John							ame and Tick Bioscience		_	,		heck all app	ationship of Reporting Person(s) to Issuer k all applicable) Director 10% Owner				
	NTYX B		E) (N CIENCES, INC REAL, SUITE		3. Date of Earliest Transaction (Month/Day/Year) 12/27/2024								belov	Officer (give title below) CHIEF SCIENTIFIC OFFICER			
(Street) SAN DIEGO CA 92130 (City) (State) (Zip)							mend	ment, Date o	of Origina	al File	d (Month/Day	v/Year)	6. Lir	ne) Form	n filed by One	o Filing (Check on Filing Per re than One Re	son
			Table	I - No	n-Deriva	tive S	ecui	rities Acq	uired	, Dis	posed of,	or Bei	nefici	ally Own	ed		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,			iction Instr.	4. Securities Disposed Of 5)			4 and Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price		ted action(s) 3 and 4)		(Instr. 4)
Common Stock 12/27/2					2024	024				21,119	D	\$2.3	6(1) 4(64,582	D		
			Tat	ole II -						•	osed of, o			•	d		
1. Title of Derivative	2. Conversi		3. Transaction Date	3A. Dec Execut	emed ion Date,	4. Transa	4. 5. Number of			6. Date Exercisable and Expiration Date 7. Title and Amount of				8. Price of Derivative	9. Number derivative	of 10. Ownership	11. Nature of Indirect

4. 5. Number 6. Date Exercisable and Expiration Date 3A. Deemed Execution Date, 1. Title of Derivative Conversion Date Amount of

Security (Instr. 3)	or Exercise Price of Derivative Security	(Month/Day/Year)	if any (Month/Day/Year)	Code (Instr. 8)		Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		(Month/Day/Year)		Securities Underlying Derivative Security (Instr. 3 and 4)		Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Represents the weighted average share price of an aggregate total of 21,119 shares sold in the price range of \$2.36 to \$2.365. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

/s/ Austin Rutherford, as Attorney-in-Fact

12/30/2024

OMB APPROVAL

3235-0287

0.5

OMB Number:

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.